The research performed in the Haibe-Kains Laboratory focuses on the integration of high-throughput data from various sources to simultaneously analyze multiple facets of diseases, with a particular emphasis on cancer. Dr. Haibe-Kains and his team are using publicly available genomic datasets and data generated through his collaboration to better understand the biology underlying diseases and to develop new predictive models in order to significantly improve disease management. Dr. Haibe-Kains's main contributions include several prognostic gene signatures in breast cancer, subtype classification models for ovarian and breast cancers, as well as genomic predictors of drug response in cancer cell lines.
Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma.
Int J Radiat Oncol Biol Phys. 2018 Feb 01;:
Administration of Hypoxia-Activated Prodrug Evofosfamide after Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Colorectal Cancer.
Clin Cancer Res. 2018 Feb 23;:
Cancer Res. 2018 Feb 19;:
Author Correction: Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Nat Commun. 2018 Jan 09;9(1):166
Semin Cancer Biol. 2017 Dec 23;:
Statin-induced cancer cell death can be mechanistically uncoupled from prenylation of RAS family proteins.
Cancer Res. 2017 Dec 11;:
Nat Biotechnol. 2017 Dec 08;35(12):1127-1128
Cancer Res. 2017 Nov 01;77(21):e39-e42
Nat Commun. 2017 Oct 24;8(1):1126
Pharmacogenomics. 2017 Oct 23;:
Scientist, Princess Margaret Cancer Centre
Assistant Professor, Department of Medical Biophysics, University of Toronto
Adjunct Assistant Professor, Department of Computer Science, University of Toronto
Ontario Institute for Cancer Research (OICR) Associate